Fasoracetam a SMART drug may prevent memory loss and reduce depression.
It was first developed in the early 1990s by the Japanese pharmaceutical company Nippon Shinyaku they were looking to treat dementia.
After spending $200 million developing it Fasoracetam failed to make it past phase 3 clinical trials.
In 2013 NeuroFix bought all the clinical data from Nippon Shinyaku and was then sold to Aevi Genomic Medicine.
They restarted the clinical trials in 2016 in ADHD, autism, or anxiety, in teenagers who have mutant glutamate receptor genes, currently, it is in phase 2 trials.
Mechanism of ACTION
Fasoracetam increases the release of acetylcholine which is a brain neurotransmitter that is very important in learning and memory.
Interestingly it also increases choline, a much-needed nutrient used in the creation and synthesis of acetylcholine that is distributed throughout the brain.
It will lead to improving the number of receptors directly inhibiting GABA (gamma-aminobutyric acid).
Fasoracetam antagonizes glutamate receptors the main excitatory neurotransmitter.
Dosage In a clinical trial (double-blind randomized controlled trial) involving ADHD patients, fasoracetam was used at doses of 100, 200, and 400 mg two times a day orally.
Anecdotally, users report effective doses between 100 and 800 mg daily. The supplement containing choline would prove extra benefit due to the increased need for acetylcholine.
Like all racetams, it increases choline uptake in the brain.
An increase in Gaba receptors along with activation of glutamate makes it a stand out in the nootropic category.
These products are certified reference material and sold for research purposes only